Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; which has completed phase II clinical trial for treating common warts; and that is in phase II clinical trial for the treatment of external genital warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
IPO Year: 2018
Exchange: NASDAQ
Website: verrica.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/6/2024 | Buy → Neutral | H.C. Wainwright | |
| 11/5/2024 | Outperform → Sector Perform | RBC Capital Mkts | |
| 7/25/2023 | $10.00 | Hold → Buy | Needham |
| 3/22/2023 | $10.00 | Buy | Jefferies |
| 2/13/2023 | $4.00 → $11.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 5/25/2022 | $16.00 → $4.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 3/10/2022 | $20.00 | Buy | Brookline Capital |
| 3/3/2022 | $20.00 → $18.00 | Buy | Needham |
| 9/22/2021 | $24.00 → $20.00 | Buy | HC Wainwright & Co. |
| 9/21/2021 | $19.00 → $16.00 | Outperform | RBC Capital |
Submission status for VERRICA PHARMACEUTICALS INC's drug YCANTH (ORIG-1) with active ingredient CANTHARIDIN has changed to 'Approval' on 07/21/2023. Application Category: NDA, Application Number: 212905, Application Classification: Type 5 - New Formulation or New Manufacturer
SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)
SC 13D/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)
SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)
SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)
SC 13G - Verrica Pharmaceuticals Inc. (0001660334) (Subject)
SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)
SC 13D - Verrica Pharmaceuticals Inc. (0001660334) (Subject)
SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)
SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)
SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)
SCHEDULE 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)
SCHEDULE 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)
S-8 - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
10-Q - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
8-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
DEFR14A - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
8-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
DEFA14A - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
DEF 14A - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
8-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
WEST CHESTER, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference in New York City. Jefferies Global Healthcare Conference, June 3-5, 2025Event details:Date: Wednesday, June 4, 2025Time: 4:20 pm ETLocation: New York, New York Participants may access a live webcast of the event by clicking the link here. The webcast can also be accessed in the Investors/P
– Company reports $3.4 million in YCANTH revenue, reflective of increasing demand, following the dispensing of more than 10,000 applicator units in the quarter, the most in company history and a 16.7% growth over Q4'24 – – Late-stage pipeline continues to advance with completion of end-of-Phase 2 meeting with Food and Drug Administration for VP-315, Verrica's candidate for basal cell carcinoma, and continued advancement towards initiation of global Phase 3 program in common warts (VP-102/YCANTH) with partner Torii Pharmaceutical – – Conference call scheduled for today at 4:30 pm ET – WEST CHESTER, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRC
WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 13, 2025, to discuss the Company's financial results for the first quarter ending March 31, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of
WEST CHESTER, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Citizens Life Sciences Conference in New York City. Citizens Life Sciences Conference, May 7-8, 2025Event details:Date: Wednesday, May 7, 2025Time: 3:00 pm ETLocation: New York Hilton Midtown, New York Participants may access a live webcast of the event by clicking the link here. The webcast can also be accessed in the Invest
– Company generated quarterly sequential growth with Q1 YCANTH® dispensed applicator units rising above 10,000 for the first time in a quarter – – As YCANTH distributor inventory levels have normalized, Company expects that dispensed applicator units will now more closely track demand and gross revenue – WEST CHESTER, Pa., April 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Company experienced strong demand-led growth for YCANTH® in the first quarter of 2025, with the number of dispensed applicato
WEST CHESTER, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Gavin Corcoran, M.D. to its Board of Directors. "We are pleased to welcome Dr. Gavin Corcoran to our Board of Directors," said Jayson Rieger, Ph.D., MBA, President and Chief Executive Officer of Verrica Pharmaceuticals. "Gavin is a highly accomplished pharmaceutical executive with an outstanding track record of successfully developing and launching innovative medicines, as well as creating significant value through strat
WEST CHESTER, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference. 24th Annual Needham Virtual Healthcare Conference, April 7-10, 2025Event details:Date: Tuesday, April 8, 2025Time: 1:30 pm ETLocation: Virtual Participants may access a live webcast of the event by clicking the link here. The webcast can also be accesse
WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Noah L. Rosenberg, M.D., as Chief Medical Officer. "We are excited to welcome Noah Rosenberg to the Verrica team as our new Chief Medical Officer," said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. "As a highly accomplished drug development executive and physician, Noah's deep expertise will significantly help our efforts to establish YCANTH® as the new standard of care for the treatment of mo
– Company generated quarterly sequential growth in YCANTH® dispensed applicator units of 12.3% in Q4'24 concurrent with significantly lower operating expenses – – Company reports positive quarterly revenue earlier than previously disclosed expectations, as new demand resulted in Company's primary distribution partner ordering applicators of YCANTH during Q4'24 – – Late-stage pipeline continues to advance with programs in basal cell carcinoma (VP-315) and common warts (VP-102/YCANTH) – – Recently strengthened balance sheet with the November 2024 $42 million public offering – – Conference call scheduled for today at 4:30 pm ET – WEST CHESTER, Pa., March 11, 2025 (GLO
WEST CHESTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, March 11, 2025, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2024, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-445-7795 (domestic) or 1-785-424-1699 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minut
4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
3 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
3 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
4/A - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
4/A - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
4/A - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
4/A - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 13, 2025, to discuss the Company's financial results for the first quarter ending March 31, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of
WEST CHESTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, March 11, 2025, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2024, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-445-7795 (domestic) or 1-785-424-1699 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minut
- Reports YCANTH® revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTH's distribution footprint to include Cencora, Inc. as a specialty distributor – - Announces positive preliminary topline results of Phase 2 clinical study of VP-315 for the treatment of patients with basal cell carcinoma – - Continues to progress preparation for global Phase 3 Common Warts trial with initiation expected in 1H 2025 – - Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical i
WEST CHESTER, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 14, 2024, to discuss the Company's financial results for the second quarter ended June 30, 2024, and provide an overview of topline results from Part 2 of the Phase 2 trial of VP-315 for the treatment of basal cell carcinoma. Individuals may participate in the live call via telephone by dialing 1-800-579-2543 (domestic) or 1-785-424-1789 (international)
– Reports YCANTH® revenue of $3.2M for first quarter of 2024 – – Over 228 million lives now covered to date on commercial insurance, managed Medicaid, Tricare and Federal Employee plans – – Preliminary Phase 2 results for VP-315 in the treatment of basal cell carcinoma (BCC) expected in the second quarter of 2024 – – Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the first quarter ended March 31, 2024. "The first quarter of 2024
WEST CHESTER, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 13, 2024 to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024. Individuals may participate in the live call via telephone by dialing 1-877-407-4018 (domestic) or 1-201-689-8471 (international) and using the conference ID: 13746100. Participants are asked to dial in 10 minutes before the start of th
– Reports YCANTH™ revenue of $1.9M for fourth quarter and $4.7M for full year 2023 – – Over 200 million lives now covered on commercial insurance and managed Medicaid plans – – Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the fourth quarter and year ended December 31, 2023. "We continued to make considerable progress with the launch of YCANTH™ during our first full quarter of commercial operations," said Ted White, Verrica's Pr
WEST CHESTER, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, February 29, 2024 to provide a corporate update and discuss the Company's financial results for the fourth quarter and full-year ended December 31, 2023. Individuals may participate in the live call via telephone by dialing 1-877-407-4018 (domestic) or 1-201-689-8471 (international) and using the conference ID: 13744217. Participants are asked to dial in 10 minu
– Strong awareness and interest in prescribing YCANTH™ among dermatologists and pediatricians – – Over 112 million lives covered to date on commercial insurance and managed Medicaid plans – – Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the third quarter ended September 30, 2023. "Following the U.S Food and Drug Administration approval of YCANTH™ for the treatment of molluscum in July, we continue to build momentum across our c
WEST CHESTER, Pa., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, November 9, 2023, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2023. Individuals may participate in the live call via telephone by dialing 1-877-407-4018 (domestic) or 1-201-689-8471 (international) and using the conference ID: 13741589. Participants are asked to dial in 10 minutes before the
– Company reported $0 in product shipments in the third quarter of 2024 and recognized negative net product revenue of $1.9 million, including a provision for product returns of $1.7 million– – Company expects existing distributor inventory to support most demand for dispensed applicator units into the first quarter of 2025 – – Company continues to look for ways to manage expenses and expand access to YCANTH® for the treatment of molluscum contagiosum – – Company announces new senior leadership with appointments of Dr. Jayson Rieger as Chief Executive Officer and John Kirby as Interim Chi
WEST CHESTER, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the second quarter ended June 30, 2021. "This quarter, we continued to ramp up commercial preparations for the potential FDA approval of VP-102, our lead product candidate for the treatment of molluscum contagiosum, including strengthening our senior leadership team and ensuring patient access to VP-102 through productive dialogue with medical providers and payors," said Ted White, Verrica's President and Chief Executive Officer. "With a
Company strengthens management team in anticipation of the potential commercial launch of VP-102, if approved WEST CHESTER, Pa., July 09, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Terry Kohler as Chief Financial Officer. Mr. Kohler is a strategic and operational finance leader with over 20 years of commercial business experience, most recently at a global pharmaceutical company with annual revenues over $2 billion. Mr. Kohler is replacing Brian Davis, who is leaving Verrica to pursue other opportunities. "Te
H.C. Wainwright downgraded Verrica Pharmaceuticals from Buy to Neutral
RBC Capital Mkts downgraded Verrica Pharmaceuticals from Outperform to Sector Perform
Needham upgraded Verrica Pharmaceuticals from Hold to Buy and set a new price target of $10.00
Jefferies initiated coverage of Verrica Pharmaceuticals with a rating of Buy and set a new price target of $10.00
RBC Capital Mkts upgraded Verrica Pharmaceuticals from Sector Perform to Outperform and set a new price target of $11.00 from $4.00 previously
RBC Capital Mkts downgraded Verrica Pharmaceuticals from Outperform to Sector Perform and set a new price target of $4.00 from $16.00 previously
Brookline Capital initiated coverage of Verrica Pharmaceuticals with a rating of Buy and set a new price target of $20.00
Needham reiterated coverage of Verrica Pharmaceuticals with a rating of Buy and set a new price target of $18.00 from $20.00 previously
HC Wainwright & Co. reiterated coverage of Verrica Pharmaceuticals with a rating of Buy and set a new price target of $20.00 from $24.00 previously
RBC Capital reiterated coverage of Verrica Pharmaceuticals with a rating of Outperform and set a new price target of $16.00 from $19.00 previously